Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

SIMVASTATIN

All products: general benefit

Other products in the same Health Canada class (C10A, C10AA) — coverage varies; not interchangeable

  • Atorvastatin (Lipitor): general benefit
  • Fluvastatin (Lescol): general benefit, Not a benefit
  • Lovastatin (Mevacor): general benefit, Not a benefit
  • Pravastatin (Pravachol): general benefit, Not a benefit
  • Rosuvastatin (Crestor): general benefit
  • Bezafibrate (Bezalip): general benefit

9 more in the class list below

Zocor · DIN 00884359 · 40mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Zocor (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Zocor · DIN 00884359 Manufacturer: Organon Canada Inc.; listing date 1996-12-19 Health Canada: Marketed since 2022-02-11 · brand ZOCOR · ATC C10AA01 SIMVASTATIN · form Tablet · route Oral · ingredients SIMVASTATIN 40 MG · company Organon canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.2501 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=46718 · Verify on the e-Formulary ↗ (DIN 00884359)

Source record
DIN 00884359: Zocor Raw flags: chronicUseMed=Y, sec3=Y Item: 240600032; group id 309; item number 0681; lccId None; manufacturer id OCI Source form: Tab; strength: 40mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $3.4841; ministry $0.2501 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00884359 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=46718
Interchangeable products
AG-Simvastatin · DIN 02480085 · $0.2501 Apo-Simvastatin · DIN 02247014 · $0.2501 Auro-Simvastatin · DIN 02405172 · $0.2501 Co Simvastatin · DIN 02248106 · $0.2501 Jamp-Simvastatin · DIN 02375621 · $0.2501 Mar-Simvastatin · DIN 02375060 · $0.2501 Mint-Simvastatin · DIN 02372967 · $0.2501 PMSC-Simvastatin · DIN 02549662 · $0.2501 Pharma-Simvastatin · DIN 02470004 · $0.2501 Ran-Simvastatin · DIN 02329174 · $0.2501 Simvastatin · DIN 02284766 · $0.2501 Simvastatin · DIN 02386321 · $0.2501 Taro-Simvastatin · DIN 02265907 · not recorded Teva-Simvastatin · DIN 02250179 · $0.2501
Shortage status: resolved shortage (ended 2024-09-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00884359
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (24:06 Antilipemic Drugs) and how they are covered

Matched class: 24:06 Antilipemic Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMLODIPINE BESYLATE & ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, BEZAFIBRATE, ROSUVASTATIN CALCIUM Some products covered without a code (check the product listing): CHOLESTYRAMINE RESIN, COLESEVELAM HYDROCHLORIDE, FENOFIBRATE, FLUVASTATIN SODIUM, GEMFIBROZIL, LOVASTATIN, PRAVASTATIN SODIUM 24:00 CARDIOVASCULAR DRUGS

INCLISIRAN

· 1 products · Limited Use, codes 732 · strengths: 284mg/1.5mL · Inj Sol-1.5mL Pref Syr Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:00 24:06 Antilipemic Drugs

ATORVASTATIN CALCIUM

· 99 products · General benefit · strengths: 10mg, 20mg, 40mg, 80mg · Tab

FLUVASTATIN SODIUM

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 20mg, 40mg, 80mg · Cap, ER Tab

LOVASTATIN

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 20mg, 40mg · Tab

PRAVASTATIN SODIUM

· 57 products · Listed, not a benefit (3), General benefit (54) · strengths: 10mg, 20mg, 40mg · Tab

ROSUVASTATIN CALCIUM

· 80 products · General benefit · strengths: 5mg, 10mg, 20mg, 40mg · Tab

BEZAFIBRATE

· 2 products · General benefit · strengths: 400mg · SR Tab

CHOLESTYRAMINE RESIN

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: · Oral Pd-Pouch Pk

COLESEVELAM HYDROCHLORIDE

· 3 products · General benefit (2), Temporary benefit (1) · strengths: 625mg · Tab

FENOFIBRATE

· 16 products · Listed, not a benefit (2), General benefit (9), Off-Formulary Interchangeable, not an ODB benefit (5) · strengths: 100mg, 67mg, 200mg, 160mg, 48mg, 145mg · Cap, Tab

GEMFIBROZIL

· 6 products · Listed, not a benefit (1), General benefit (2), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 300mg, 600mg · Cap, Tab

EVOLOCUMAB

· 1 products · Limited Use, codes 527, 737 · strengths: 140mg/mL · Inj Sol-Pref Syr Autoinj Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:06 and 4 more
Full class listing Related classes: 24:04 Cardiac Drugs, 24:08 Hypotensive Drugs (For Diuretics See 40:28), 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS ZOCOR® (simvastatin) is indicated in adults as an adjunct to diet for: • Reduction of risk of total mortality, myocardial infarction and ischemic stroke in patients with high risk of coronary events (because of existing Coronary Heart Disease (CHD), occlusive arterial disease, or diabetic over the age of 40) regardless of their lipid status. • Slowing progression of coronary atherosclerosis, including reducing the development of new lesions and new total occlusions in hypercholesterolemic patients with CHD. • Reduction of elevated total cholesterol (total-C) and Low-Density Lipoprotein- cholesterol (LDL-C), apolipoprotein B (apo B), and triglycerides (TG) levels in patients with primary hypercholesterolemia (Type IIa)† or combined (mixed) hyperlipidemia (Type IIb) 1.1 Pediatrics Pediatric Patients with Heterozygous Familial Hypercholesterolemia • 10-<18 years of age ZOCOR® is indicated as an adjunct to diet in adolescent boys and girls who are at least one year post-menarche aged 10 to <18 years to reduce total-C, LDL-C, TG, and Apo B levels with heterozygous familial… https://pdf.hres.ca/dpd_pm/00071846.PDF PM date: AUG 29, 1990 Source product: ZOCOR; DIN 00884332; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.